224 related articles for article (PubMed ID: 30292834)
1. Solubility changes of promyelocytic leukemia (PML) and SUMO monomers and dynamics of PML nuclear body proteins in arsenite-treated cells.
Hirano S; Udagawa O; Kobayashi Y; Kato A
Toxicol Appl Pharmacol; 2018 Dec; 360():150-159. PubMed ID: 30292834
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation regulates the number and size of promyelocytic leukemia-nuclear bodies (PML-NBs) and arsenic perturbs SUMO dynamics on PML by insolubilizing PML in THP-1 cells.
Hirano S; Udagawa O
Arch Toxicol; 2022 Feb; 96(2):545-558. PubMed ID: 35001170
[TBL] [Abstract][Full Text] [Related]
3. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
4. Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.
Percherancier Y; Germain-Desprez D; Galisson F; Mascle XH; Dianoux L; Estephan P; Chelbi-Alix MK; Aubry M
J Biol Chem; 2009 Jun; 284(24):16595-16608. PubMed ID: 19380586
[TBL] [Abstract][Full Text] [Related]
5. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
6. Effects of arsenic on the topology and solubility of promyelocytic leukemia (PML)-nuclear bodies.
Hirano S; Udagawa O
PLoS One; 2022; 17(5):e0268835. PubMed ID: 35594310
[TBL] [Abstract][Full Text] [Related]
7. Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.
Maroui MA; Kheddache-Atmane S; El Asmi F; Dianoux L; Aubry M; Chelbi-Alix MK
PLoS One; 2012; 7(9):e44949. PubMed ID: 23028697
[TBL] [Abstract][Full Text] [Related]
8. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
9. NS5 Sumoylation Directs Nuclear Responses That Permit Zika Virus To Persistently Infect Human Brain Microvascular Endothelial Cells.
Conde JN; Schutt WR; Mladinich M; Sohn SY; Hearing P; Mackow ER
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699085
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
11. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
12. The promyelocytic leukemia protein isoform PML1 is an oncoprotein and a direct target of the antioxidant sulforaphane (SFN).
Alhazmi N; Pai CP; Albaqami A; Wang H; Zhao X; Chen M; Hu P; Guo S; Starost K; Hajihassani O; Miyagi M; Kao HY
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118707. PubMed ID: 32243901
[TBL] [Abstract][Full Text] [Related]
13. An L2 SUMO interacting motif is important for PML localization and infection of human papillomavirus type 16.
Bund T; Spoden GA; Koynov K; Hellmann N; Boukhallouk F; Arnold P; Hinderberger D; Florin L
Cell Microbiol; 2014 Aug; 16(8):1179-200. PubMed ID: 24444361
[TBL] [Abstract][Full Text] [Related]
14. Regulation of Pax3 transcriptional activity by SUMO-1-modified PML.
Lehembre F; Müller S; Pandolfi PP; Dejean A
Oncogene; 2001 Jan; 20(1):1-9. PubMed ID: 11244500
[TBL] [Abstract][Full Text] [Related]
15. Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.
Tatemichi Y; Shibazaki M; Yasuhira S; Kasai S; Tada H; Oikawa H; Suzuki Y; Takikawa Y; Masuda T; Maesawa C
Cancer Sci; 2015 Jul; 106(7):848-56. PubMed ID: 25891951
[TBL] [Abstract][Full Text] [Related]
16. SUMO5, a Novel Poly-SUMO Isoform, Regulates PML Nuclear Bodies.
Liang YC; Lee CC; Yao YL; Lai CC; Schmitz ML; Yang WM
Sci Rep; 2016 May; 6():26509. PubMed ID: 27211601
[TBL] [Abstract][Full Text] [Related]
17. Role of SUMO-1-modified PML in nuclear body formation.
Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
[TBL] [Abstract][Full Text] [Related]
18. Effects of arsenic on modification of promyelocytic leukemia (PML): PML responds to low levels of arsenite.
Hirano S; Watanabe T; Kobayashi Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):590-9. PubMed ID: 24135626
[TBL] [Abstract][Full Text] [Related]
19. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
20. The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Reuter N; Schilling EM; Scherer M; Müller R; Stamminger T
J Virol; 2017 May; 91(10):. PubMed ID: 28250117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
